Edition:
United States

Oncopeptides AB (ONCO.ST)

ONCO.ST on Stockholm Stock Exchange

154.00SEK
16 Nov 2018
Change (% chg)

7.00kr (+4.76%)
Prev Close
147.00kr
Open
151.40kr
Day's High
154.00kr
Day's Low
148.40kr
Volume
63,782
Avg. Vol
108,285
52-wk High
209.00kr
52-wk Low
73.20kr

Latest Key Developments (Source: Significant Developments)

Oncopeptides Completes A Directed Share Issue
Thursday, 22 Mar 2018 03:00am EDT 

March 22 (Reuters) - Oncopeptides Ab ::ONCOPEPTIDES HAS COMPLETED A DIRECTED SHARE ISSUE OF APPROXIMATELY SEK 314 MILLION.‍SUCCESSFULLY COMPLETED A DIRECTED SHARE ISSUE OF APPROXIMATELY SEK 314 MILLION (USD 38 MILLION)​.  Full Article

Oncopeptides To Make A Directed Share Issue
Wednesday, 21 Mar 2018 12:31pm EDT 

March 21 (Reuters) - Oncopeptides Ab ::ONCOPEPTIDES INTENDS TO MAKE A DIRECTED SHARE ISSUE.SAYS ‍SUBSCRIPTION PRICE AND TOTAL NUMBER OF NEW SHARES IN ISSUE WILL BE DETERMINED THROUGH AN ACCELERATED BOOKBUILD PROCEDURE, NUMBER OF NEW SHARES WILL NOT EXCEED 3,980,000.​.  Full Article

Oncopeptides Additional Patent Protection For Ygalo In Japan
Thursday, 8 Mar 2018 02:00am EST 

March 8 (Reuters) - Oncopeptides Ab ::ADDITIONAL PATENT PROTECTION FOR YGALO® HAS BEEN GRANTED IN JAPAN UNTIL 2033.  Full Article

Oncopeptides Q4 Net Loss Up At Sek ‍66.7​ Million
Thursday, 22 Feb 2018 02:00am EST 

Feb 22 (Reuters) - Oncopeptides Ab ::Q4 NET LOSS SEK ‍66.7​ MILLION VERSUS LOSS SEK 51.1 MILLION YEAR AGO.  Full Article

Oncopeptides Q3 operating ‍loss widens to SEK 51.6 million
Wednesday, 15 Nov 2017 02:04am EST 

Nov 15 (Reuters) - ONCOPEPTIDES AB :Q3 OPERATING ‍LOSS SEK 51.6 MILLION VERSUS LOSS SEK 24.7 MILLION YEAR AGO​.  Full Article

Oncopeptides Q2 loss for period widens to SEK 67.3 mln​
Friday, 25 Aug 2017 02:00am EDT 

Aug 25 (Reuters) - ONCOPEPTIDES AB :‍Q2 LOSS FOR PERIOD WAS 67.3 (LOSS: 23.5) MSEK​.  Full Article

Oncopeptides Q1 net loss SEK 62.1 million
Thursday, 18 May 2017 02:00am EDT 

May 18 (Reuters) - ONCOPEPTIDES AB :Q1 NET SALES AMOUNTED TO 0.0 (0.0) MSEK.Q1 LOSS FOR PERIOD WAS 62.1 (LOSS: 15.2) MSEK.  Full Article

Oncopeptides receives additional patent protection for Ygalo in Europe
Tuesday, 21 Mar 2017 03:45am EDT 

Oncopeptides AB : European patent office recently issued a notice that they intend to grant an additional European patent to Oncoeptides . Additional patent protection for Ygalo is valid April 2032 .Patent (EP2701720) covers inter alia lyophilized formulation of Ygalo that is intended to be launched.  Full Article